The Evaluation Remedsivir efficacy and effect in patients with COVID-19 admitted in Imam Reza Hospital; A descriptive study

Abstract

The rapid spread of the contagious coronavirus on March 11th, 2020 caused widespread concern. Remdesivir is the first drug approved by FDA against coronavirus for hospitalized patients. There are some controversial studies on the efficacy of this drug. Based on this, the efficacy of this drug to treat patients with COVID-19 was investigated. Aim: Mortality rate of patients who were hospitalized in Imam Reza hospital, the need for oxygen, the hospitalization in ICU, and the hospitalization duration in the non-intensive care unit of the hospital were evaluated.Methods: The patient's information was recorded in the form of a questionnaire. All of included patients had clinical criteria for COVID-19 or a positive PCR test.. Demographic and laboratory information, time of hospitalization, the time of the transferring the patients to ICU, and finally, the need for ventilation or high flow nasal canula and survival or discharge were recorded. The other drugs that the patients had received were also recorded for the evaluation simultaneously.Results: The patients’ average age was 60 and 53.5% of them were men. 343 patients received Remdesivir among 706 that had been hospitalized in hospital and 30% of those 343 patients died. When the patients were hospitalized, Shortness of breath, cough and myalgia were most of the symptoms and obesity, high blood pressure and diabetes were most of the background diseases.Conclusion: Remdesivir did not have an effect on the patients’ deaths and decreased the duration of the hospitalization and also increases the hospitalization of patients in the ICU. Age over 60, high blood pressure, the number of CPR over 100, the number of D-dimer over 1000 and the number of lymphocytes below 800 can be mentioned as the risk factors of the disease